Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe page footer now displays Revision: v3.5.5, replacing Revision: v3.5.4. This indicates a minor update to the page's revision history without changing its content.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe study locations list now includes Taebuk, Chungcheongbuk-do, South Korea (28644) and previously listed Jungbuk (28644) was removed; the page revision was updated from v3.5.3 to v3.5.4.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedThe revision tag has been updated to v3.5.3, replacing the previous v3.5.0 in the revision history. This represents a metadata update with no substantive changes to the study details.SummaryDifference0.0%

- Check59 days agoChange DetectedThe Veneto, Italy site listing changed from Padua to Padova (postal code 35128).SummaryDifference0.0%

- Check66 days agoChange DetectedA new publication citation has been added to the Publications section: 'Assessing side-effect bother, burden, and tolerability: A qualitative study exploring the content validity of the Functional Assessment of Cancer Therapy - Item GP5.' This reference provides additional context for the study's reported outcomes but does not modify study design or participant information.SummaryDifference0.0%

- Check73 days agoChange DetectedNapoli, Campania, Italy, 80131 was renamed to Naples, Campania, Italy, 80131 and a Naples listing was added, with the page revision updated to v3.5.0.SummaryDifference0.1%

Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.